Integrated pharmacological and structural profiling reveals CB1 residue interaction patterns associated with synthetic cannabinoid receptor agonist efficacy

A recent study delves into the pharmacological profiles and structural features of 16 synthetic cannabinoid receptor agonists (SCRAs). These SCRAs, which are diverse synthetic substances, exhibit a wide range of cannabinoid receptor 1 (CB1) potency and efficacy. However, the molecular and receptor-interaction features responsible for these differences have been largely unexplored.

Researchers employed a CB1-G15-based Ca2+ assay to measure CB1 agonist activity and conducted cataleptic effect assessments in mice. Molecular docking was used to characterize ligand-receptor interactions, and principal component analysis (PCA) was applied to residue-level interaction profiles. The resulting scores were then tested for associations with CB1 potency and efficacy.

The findings revealed significant variations in potency and efficacy across both in vitro and in vivo assays, with some compounds displaying differing pharmacological profiles between systems. PCA identified an interaction pattern whose PC1 scores were significantly associated with the Emax, but not the EC50, with contributions from activation-related CB1 residues, including the PHE200-TRP356 toggle switch.

Additionally, molecular descriptor analysis identified structural features that were significantly associated with in vitro and in vivo Emax. These results suggest that CB1 efficacy is linked to distinct receptor-interaction patterns among structurally diverse SCRAs. By combining functional pharmacology with receptor-level interaction analysis, this study offers structural insights into SCRA efficacy, potentially aiding in the prioritization of emerging compounds for further pharmacological and behavioral evaluation.